iData Insights

Nephropathy - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 30, 2016 11:56 IST

Nephropathy - Pipeline Review, H2 2015 Summary Global Markets Direct s, Nephropathy - Pipeline Review, H2 2015, provides an overview of the Nephropathys therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nephropathy and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Nephropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Nephropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Nephropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Nephropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Nephropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Nephropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @

To Get Sample Copy of Report visit @

Table of Contents

Introduction 5

Global Markets Direct Report Coverage 5

Nephropathy Overview 6

Therapeutics Development 7

Pipeline Products for Nephropathy - Overview 7

Nephropathy - Therapeutics under Development by Companies 8

Nephropathy - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Nephropathy - Products under Development by Companies 12

Nephropathy - Companies Involved in Therapeutics Development 13

Anthera PharmaceuticalsInc. 13

Boehringer Ingelheim GmbH 14

ChemoCentryx, Inc. 15

Complexa, Inc. 16

Promedior, Inc. 17

Nephropathy - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

blisibimod - Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

CCX-168 - Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

CXA-10 - Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

imatinib mesylate - Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

PRM-151 - Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

R-801 - Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

R-901 - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Small Molecule to Inhibit Casein Kinase 2 for Cancer and Nephritis - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

Nephropathy - Recent Pipeline Updates 42

Nephropathy - Dormant Projects 52

Nephropathy - Discontinued Products 53

Nephropathy - Product Development Milestones 54

Featured News & Press Releases 54

Mar 16, 2015: Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for IgA Nephropathy 54

Oct 01, 2014: Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions For Blisibimod 54

Sep 25, 2013: Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting 54

Jun 24, 2013: Anthera Pharma Initiates BRIGHT-SC Phase II Clinical Study In IgA Nephropathy With Blisibimod 55

Appendix 56

Methodology 56

Coverage 56

Secondary Research 56

Primary Research 56

Expert Panel Validation 56

Contact Us 56

Disclaimer 57

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects